Latest Episodes
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on...
Michael Gold, Chief R&D Officer at Compass Pathways
In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running...
Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development
Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares...
6
Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment
Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate,...
5
Backing Breakthroughs in Psychedelics
Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed...
4
Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry
Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research...